SIGA Technologies Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIGA Technologies Inc.

SIGA 8.280

-0.4%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: caly who wrote (116)	12/11/2009 11:10:57 PM
From: caly	Read Replies (1) of 160

Compliments of posters on Yahoo... On Dec. 11th, BARDA issued an amendment to the original RFP that loosens the initial requirements for eligibility to respond and delays the eventual award. SMALLPOX ANTIVIRAL FOR THE STRATEGIC NATIONAL STOCKPILE fbo.gov There will be two significant changes made to the RFP. First, under Section L.5. (Type of Contract and Number of Awards), the United States Government (USG) now contemplates one or more awards of a five-year hybrid Firm Fixed Price/Cost Reimbursable type contract for MCMs that can provide treatment for individuals exposed to smallpox. Second, under Section M.1. (Mandatory Criteria for Eligibility), although the Offeror will still need to provide evidence for therapeutic index in non-human primate model under an eventual contract, the USG is willing to forego this mandatory criterion for eligibility at this time. All other mandatory criteria for eligibility will remain unchanged.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next